68Ga-NOTA-AE105 uPAR PET 对神经内分泌肿瘤患者预后判断的前瞻性 II 期试验:对 uPAR 靶向治疗的意义
前瞻性 II 期试验纳入 116 例神经内分泌肿瘤(NEN)患者,其中 96 例可评估者行 68Ga-NOTA-AE105 uPAR PET/CT,68% 见 uPAR 阳性病灶。中位随访 28 个月,uPAR 靶本肝比高于中位数者无进展生存(HR 1.87,95%CI 1.11-3.17)与总生存(HR 2.64,95%CI 1.19-5.88)均更差。作者建议 uPAR PET 可用于风险分层,uPAR 可能是 NEN 有前景的治疗靶点。
要点
- uPAR PET/CT 在 68% 的 NEN 患者中检出 uPAR 阳性病灶,高级别(3 级)患者中为 75%。
- uPAR 靶本肝比高于中位数者无进展生存 HR 1.87(95%CI 1.11-3.17)。
- uPAR 靶本肝比高于中位数者总生存 HR 2.64(95%CI 1.19-5.88)。
核心结论
- 68Ga-NOTA-AE105 PET 显像时,多数 NEN 患者可见 uPAR 阳性病灶,低级别与高级别 NEN 均可见。
- uPAR 表达与更差预后相关。
- 作者建议 uPAR PET 可用于风险分层,并认为 uPAR 可能是 NEN 患者有前景的治疗靶点。
研究设计与样本
- 前瞻性临床 II 期试验纳入 116 例全级别 NEN 患者,其中 96 例随后行 uPAR PET/CT 且有可评估病灶。
- 注射约 200 MBq 68Ga-NOTA-AE105 后 20 分钟行 PET/CT,病灶 SUVmax 与肝脏 SUVmean 比值至少 2 定义为 uPAR 阳性。
- 患者随访至少 1 年以评估无进展生存与总生存。
主要发现
- 多数患者为小肠 NEN(n=61)和转移性疾病(n=86)。
- 全部患者中 68%(n=65)见 uPAR 阳性病灶,高级别(3 级)NEN 患者中为 75%(n=18)。
- 随访中位 28 个月期间,59 例(62%)出现疾病进展,28 例(30%)死亡。
- uPAR 靶本肝比高于中位数者无进展生存 HR 1.87(95%CI 1.11-3.17),总生存 HR 2.64(95%CI 1.19-5.88),两者 P<0.05。
关键数值与推荐
- uPAR 阳性定义为病灶 SUVmax 与肝脏 SUVmean 比值至少 2。
- 高 uPAR 表达定义为 uPAR 靶本肝比高于中位数。
临床怎么用
- 作者建议 uPAR PET 可用于 NEN 患者的风险分层。
- 作者认为 uPAR 可能是 NEN 患者有前景的治疗靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical course for patients with neuroendocrine neoplasms (NENs) ranges from indolent to highly aggressive. Noninvasive tools to improve prognostication and guide decisions on treatment are warranted. Expression of urokinase plasminogen activator receptor (uPAR) is present in many cancer types and associated with a poor outcome. Therefore, using an in-house-developed uPAR PET tracer [68Ga]Ga-NOTA-Asp-Cha-Phe-D-Ser-D-Arg-Tyr-Leu-Trp-Ser-OH (68Ga-NOTA-AE105), we aimed to assess uPAR expression in NENs. We hypothesized that uPAR expression was detectable in a significant proportion of patients and associated with a poorer outcome. In addition, as uPAR-targeted radionuclide therapy has previously proven effective in preclinical models, the study would also indicate the potential for uPAR-targeted radionuclide therapy in NEN patients. Methods: In a prospective clinical phase II trial, we included 116 patients with NENs of all grades, of whom 96 subsequently had uPAR PET/CT performed with evaluable lesions. PET/CT was performed 20 min after injection of approximately 200 MBq of 68Ga-NOTA-AE105. uPAR target-to-liver ratio was used to define lesions as uPAR-positive when lesion SUVmax-to-liver SUVmean ratio was at least 2. Patients were followed for at least 1 y to assess progression-free and overall survival. Results: Most patients had small intestinal NENs (n = 61) and metastatic disease (n = 86). uPAR-positive lesions were seen in 68% (n = 65) of all patients and in 75% (n = 18) of patients with high-grade (grade 3) NENs. During follow-up (median, 28 mo), 59 patients (62%) experienced progressive disease and 28 patients (30%) died. High uPAR expression, defined as a uPAR target-to-liver ratio above median, had a hazard ratio of 1.87 (95% CI, 1.11-3.17) and 2.64 (95% CI, 1.19-5.88) for progression-free and overall survival, respectively (P < 0.05 for both). Conclusion: When 68Ga-NOTA-AE105 PET was used to image uPAR in patients with NENs, uPAR-positive lesions were seen in most patients, notably in patients with both low-grade and high-grade NENs. Furthermore, uPAR expression was associated with a worse prognosis. We suggest that uPAR PET is relevant for risk stratification and that uPAR may be a promising target for therapy in patients with NENs.
引用
- Carlsen EA, Loft M, Loft A, et al. Prospective Phase II Trial of Prognostication by 68Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy. J Nucl Med. 2022. PMID: 35058319. doi:10.2967/jnumed.121.263177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。